知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

2310 条记录 (耗时 0.061 秒)

    Indoleamine 2,3-dioxygenase based immunotherapy
    83.
    发明授权
    Indoleamine 2,3-dioxygenase based immunotherapy 有权
    吲哚胺2,3-双加氧酶基免疫疗法

    公开(公告)号：US09433666B2

    公开(公告)日：2016-09-06

    申请号：US12988124

    申请日：2009-04-17

    申请人： Mads Hald Andersen ,  Per Thor Straten

    发明人： Mads Hald Andersen ,  Per Thor Straten

    IPC分类号： A61K39/395 ,  A61K39/00 ,  A61K38/19 ,  A61K38/20

    CPC分类号： A61K39/0011 ,  A61K38/193 ,  A61K38/2013 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/55566 ,  A61K2039/572 ,  C12N9/0069 ,  C12Y113/11052 ,  Y02A50/491 ,  A61K2300/00

    摘要： The present invention relates to the field of prophylaxis and therapy of cancer. In particular there is provided a protein Indoleamine 2,3-dioxygenase (IDO) or peptide fragments here of that are capable of eliciting anti-cancer immune responses. Specifically, the invention relates to the use of DO or peptides derived here from or IDO specific T-cells for treatment of cancer. The invention thus relates to an anti-cancer vaccine which optionally may be used in combination with other immunotherapies and to IDO specific T-cells adoptively transferred or induced in vivo by vaccination as a treatment of cancer. It is an aspect of the invention that the medicaments herein provided may be used in combination with cancer chemotherapy treatment. A further aspect relates to the prophylaxis and therapy of infections by the same means as described above. The use of IDO and immunogenic peptide fragments hereof in cancer and infection treatment, diagnosis and prognosis is also provided.

    摘要翻译： 本发明涉及癌症的预防和治疗领域。 特别地，提供了能够引发抗癌免疫应答的蛋白质吲哚胺2,3-双加氧酶（IDO）或肽片段。 具体地说，本发明涉及使用DO或来自这里的肽或IDO特异性T细胞用于治疗癌症。 因此，本发明涉及一种抗癌疫苗，其任选地可以与其它免疫疗法组合使用，以及通过接种过继转移或诱导的IDO特异性T细胞作为癌症治疗。 本发明的一个方面是提供的药物可以与癌症化学疗法组合使用。 另一方面涉及通过与上述相同的方法预防和治疗感染。 还提供了在癌症和感染治疗，诊断和预后中使用IDO和免疫原性肽片段。

    Method for bone marrow preservation or recovery
    89.
    发明授权
    Method for bone marrow preservation or recovery 有权
    骨髓保存或恢复方法

    公开(公告)号：US09402882B2

    公开(公告)日：2016-08-02

    申请号：US12756995

    申请日：2010-04-08

    申请人： Tingchao Chen ,  Yi Zhao ,  W. French Anderson

    发明人： Tingchao Chen ,  Yi Zhao ,  W. French Anderson

    IPC分类号： A61K38/20 ,  C07K14/54 ,  A61P35/02 ,  A61P7/06 ,  A61K45/06 ,  A61N5/10 ,  A61K31/675

    CPC分类号： A61K38/208 ,  A61K31/675 ,  A61K38/193 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1098 ,  C07K14/53 ,  C07K14/5434 ,  A61K2300/00

    摘要： Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hematopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery.

    摘要翻译： 用于增强或刺激造血的方法，包括施用白细胞介素-12（IL-12）以在需要的哺乳动物中产生造血回收的步骤。 优选的方法包括施用IL-12作为辅助治疗以减轻与用于对抗疾病状态的一种或多种治疗方案相关的造血毒性的步骤。 其他方法包括给予IL-12以改善各种造血缺陷。 还有其它方法涉及IL-12用于造血再生细胞，造血祖细胞和造血干细胞的体内增殖的用途。 其他公开的方法涉及IL-12用于骨髓保存或恢复的用途。

    Compositions for Liquidation of Tumors
    90.
    发明申请
    Compositions for Liquidation of Tumors 审中-公开
    肿瘤清理组合物

    公开(公告)号：US20160206718A1

    公开(公告)日：2016-07-21

    申请号：US15084206

    申请日：2016-03-29

    申请人： Immunovative Therapies, Ltd.

    发明人： Michael Har-Noy

    IPC分类号： A61K39/00

    CPC分类号： A61K39/0011 ,  A61B18/02 ,  A61B18/12 ,  A61B2018/00613 ,  A61K38/191 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/208 ,  A61K38/217 ,  A61K39/00 ,  A61K2039/5154 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/57

    摘要： This invention relates to compositions and methods for immunotherapy of cancer. Specifically, a method of cancer immunotherapy is described which results in the systemic liquidation of both solid and metastatic tumors whereever they reside in the body. The compositions include activated allogeneic Th1 cells that when administered appropriately lead to liquidation of tumors. The method includes administering priming doses of the therapeutic composition, ablation of a selected tumor lesion along with intratumoral injection of the composition and then infusion of the therapeutic composition. These steps enable the systemic liquidation of tumors secondary to immune cell infiltration and leads to immune-mediated tumor eradication.

    摘要翻译： 本发明涉及癌症免疫治疗的组合物和方法。 具体地，描述了一种癌症免疫治疗方法，其导致无论身体存在于固体和转移性肿瘤中的系统性清除。 组合物包括活化的同种异体Th1细胞，其当被适当地施用导致肿瘤的清除时。 该方法包括施用引发剂量的治疗组合物，消融所选择的肿瘤损伤以及肿瘤内注射组合物，然后输注治疗组合物。 这些步骤使得免疫细胞浸润继发的肿瘤的系统性清除并导致免疫介导的肿瘤根除。